Results of cuffless blood pressure monitor presented at AHA Hypertension Sessions


Results of an analysis of Aktiia’s cuffless blood pressure (BP) monitoring system are being presented at the American Heart Association (AHA) Hypertension Scientific Sessions 2022 (7–10 September, San Diego, USA).

The analysis has been co-authored by experts from Barts NIHR Biomedical Research Centre (London, UK), Scripps Translational Research Institute (La Jolla, USA), Lausanne University Hospital (Lausanne, Switzerland), Brigham and Women’s Hospital (Boston, USA), and Mayo Clinic (Phoenix, USA) and demonstrates that hypertensive patients who monitor their BP with Aktiia’s 24/7 BP monitor achieve a significant and sustained reduction in systolic BP.

Aktiia’s optical continual BP monitor has been available for purchase in seven European countries since March 2021. By design and purpose, Aktiia’s passive and continual collection of BP data has quickly compiled over 55,000,000 data points in real-world conditions, establishing the largest dataset of BP readings in the world which uniquely enables Aktiia and its partners to unlock new insights into hypertension, the company said in a press release.

The objective of Aktiia’s recent investigation was to explore whether a change in behaviour resulting in measurably lower BP would be demonstrated in hypertensive subjects who were consistently exposed to their BP data via Aktiia’s integrated mobile app.

The analysis concluded that mean SBP was reduced in -3.2 mmHg (confidence interval: [-0.70, -5.59], p<0.02) for hypertensive users (SBP > 140 mmHg) following 3 months of continual cuffless BP monitoring (Figure 2). This reduction was then sustained throughout the 6 months studied. Mean SBP remained unchanged for normotensive users (SBP < 140 mmHg).

The powerful relationship between BP reduction and reduction of cardiovascular events is undisputed, irrespective of the mechanism for the reduction, the company’s press release adds, noting that even a 5mmHg reduction in systolic BP reduces cardiovascular risk by 10%.

“These data highlight just the beginning of the tremendous value of Aktiia’s dataset across the hypertension care continuum,” the company states.


Please enter your comment!
Please enter your name here